FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval Transcript

preview_player
Показать описание
The D.I.S.C.O. hosts discuss the agency’s first approval of a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.

Transcript
  1. U.S. Food and Drug Administration
Рекомендации по теме
Clinical Workshop:Tumor Agnostic 1:08:56

Clinical Workshop:Tumor Agnostic Approaches to Care

76th Cellular, Tissue, 7:11:00

76th Cellular, Tissue, and Gene Therapies Advisory Committee

September 26, 2024 9:00:31

September 26, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)

123rd Meeting of 2:22:31

123rd Meeting of the Blood Products Advisory Committee (BPAC)

Conversations on Cancer: 1:00:08

Conversations on Cancer: Cancer Moonshot: What’s happened since 2017?

Master Protocols from 0:23:04

Master Protocols from a Regulatory Perspective - Margit Horiba, FDA (D3P16)

Implementation of FDA-cleared 0:58:18

Implementation of FDA-cleared tumor profiling assay to enable localized Precision Oncology testing

72nd Cellular, Tissue 5:14:50

72nd Cellular, Tissue and Gene Therapies Advisory Committee - Day 2

September 11-12, 2023 8:22:00

September 11-12, 2023 Meeting of the Nonprescription Drugs Advisory Committee (NDAC) - Day 1

FDA EMA immunogenicity 0:46:41

FDA EMA immunogenicity guidelines APR2020

2023 TOP FDA 2:59:01

2023 TOP FDA Diagnostic Data Solutions Showcase

March 15, 2024 9:08:15

March 15, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)

Organogenesis - Company 0:13:23

Organogenesis - Company Presentation

Personalized Medicine in 1:45:00

Personalized Medicine in Solid Tumors

Does Real World 1:02:06

Does Real World Evidence have a role in Precision Oncology

Laboratory Medicine and 0:41:26

Laboratory Medicine and Pathology in Individualized Medicine: A Guide to Cancer Treatment

Next-Generation Sequencing and 0:16:21

Next-Generation Sequencing and Targets in Early-Phase Colorectal Cancer Drug Development

How to Optimize 0:57:02

How to Optimize Your Drug Label Using Biosimulation Methodology

The Evolution of 0:50:28

The Evolution of Precision Diagnostics in Advancing Treatment Strategies of Solid Tumors

11/10/2014 - Session 0:22:48

11/10/2014 - Session 2A - Overview of FDA Regulations for Diagnostics

Advancing the Development 6:10:51

Advancing the Development and Implementation of Analysis Data Standards

LMSDR Conference 2024 0:56:28

LMSDR Conference 2024 Session #4: LMS Research with Dr. Agulnik

KEYNOTE: Gregory Reaman, 0:53:04

KEYNOTE: Gregory Reaman, M.D., Associate Director of Oncology Sciences, U.S. FDA

Synthetic Control Arms 0:59:44

Synthetic Control Arms and The Regulatory Maze